Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.

Launched by INSTITUT BERGONIÉ · Nov 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread to other parts of the body. The researchers want to understand how the radiation from this treatment affects both the tumor and nearby organs, which could help predict how well the treatment works and if it causes any side effects. They will use special imaging techniques to measure the dose of radiation delivered during each treatment.

To participate in this study, patients need to be 18 years or older and have prostate cancer that is progressive and resistant to standard hormone therapies. They should have already started or completed treatment with 177Lu-PSMA-617 since November 1, 2023, and have received certain previous therapies. Participants will need to be able to lie still for about an hour for imaging, and they should live within a two-hour drive from the Institut Bergonié. There are no specific exclusions for this trial, so if you meet the criteria, you may be eligible to help contribute to important research in prostate cancer treatment.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient aged 18 and over.
• 2. Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01/11/2023:
• • 1. Progressive, metastatic, castration-resistant prostate cancer,
• • 2. overexpressing prostate specific membrane antigen (PSMA)
• • 3. treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone).
• • 3. Patient able to lie still for 1 hour for image acquisition.
• • 4. Patient's place of residence \< 2 hours' drive from the Institut Bergonié.
• • 5. Patient has not expressed any opposition to the use of his/her medical data for research purposes.
• Exclusion Criteria:
• • None